Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

OBJECTIVES. In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival benefit in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation who were in response after platinum-based chemotherapy. We analyzed the timing, duration...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Nicoletta, Moore, Kathleen, Scambia, Giovanni, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S., Gourley, Charlie, Banerjee, Susana, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William H., Kim, Jae-Weon, Mathews, Cara, Liu, Joyce, Lowe, Elizabeth S., Bloomfield, Ralph, DiSilvestro, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555119/
https://www.ncbi.nlm.nih.gov/pubmed/34353615
http://dx.doi.org/10.1016/j.ygyno.2021.07.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555119/
https://www.ncbi.nlm.nih.gov/pubmed/34353615
http://dx.doi.org/10.1016/j.ygyno.2021.07.016

Ejemplares similares